Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

Fintel reports that on May 19, 2025, RBC Capital downgraded their outlook for Biohaven (NYSE:BHVN) from Outperform to Sector ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called spinocerebellar ataxia. Read more here.

RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $54.00. The company’s shares closed y ...

Morgan Stanley analyst Terence Flynn reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $63.00. The company’s shares closed yest ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday ...

In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial ...

Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

BHVN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.